Table 2.
Number of Events, Person-Years, and Event Rates for Major Mobility Disability and Injurious Falls by Medication Use and Intervention Arm
| Outcome | Physical activity | Health education | ||||
|---|---|---|---|---|---|---|
| Events, N (%) | Person-years (PY) | Events/100 PY | Events, N (%) | Person-Years (PY) | Events/100 PY | |
| MMDa | ||||||
| ACEi | 81 (32.5) | 533.02 | 15.2 | 98 (40.3) | 498.83 | 19.7 |
| ARB | 37 (26.1) | 327.73 | 11.3 | 56 (35.9) | 354.92 | 15.8 |
| Persistent MMDa | ||||||
| ACEi | 42 (16.9) | 547.62 | 7.7 | 66 (27.2) | 521.00 | 12.7 |
| ARB | 16 (11.3) | 336.22 | 4.8 | 34 (21.8) | 368.65 | 9.2 |
| Injurious fallsa | ||||||
| ACEi | 31 (12.4) | 646.35 | 4.8 | 30 (12.3) | 605.79 | 5.0 |
| ARB | 15 (10.6) | 336.77 | 4.5 | 18 (11.5) | 384.07 | 4.7 |
Note: ACEi = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers; MMD = major mobility disability.
aAll rate comparisons were nonsignificant between ACEi and ARB groups (p > .05).